Loxapine Inahlation Powder Suppliers & Bulk Manufacturers
Available Forms: Inhalation Powder (single-use oral inhaler)
Available Strengths: 10 mg
Reference Brands: Adasuve®(US & EU)
Category:
Antipsychotropic Drugs
Loxapine inhalation powder is a typical antipsychotic that works by antagonizing dopamine D2 and serotonin 5-HT2 receptors in the brain, helping to quickly reduce agitation. It is used for the acute treatment of agitation in adults with schizophrenia or bipolar I disorder. The inhaled form allows for rapid onset of action (within 10 minutes), making it ideal for emergency psychiatric settings while avoiding injectable routes.
Loxapine Inahlation powder is available in Inhalation Powder (single-use oral inhaler)
and strengths such as 10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Loxapine Inahlation powder is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Loxapine Inahlation powder can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Loxapine inhalation powder is FDA-approved in the U.S. under the brand Adasuve for the acute treatment of agitation associated with schizophrenia and bipolar I disorder. In the EU, it is authorized under EMA regulation with Risk Evaluation and Mitigation Strategy (REMS) and mandatory pulmonary function monitoring due to bronchospasm risk. Regulatory submissions must include clinical safety data, device compatibility, and GMP compliance for combination drug-device products. For global buyers and distributors seeking dossier-ready forms of Loxapine inhalation powder or other delivery formats, visit Pharmatradz.com — your B2B gateway to trusted pharmaceutical manufacturers and suppliers.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing